Zacks Research Decreases Earnings Estimates for Henry Schein

Henry Schein, Inc. (NASDAQ:HSIC) – Stock analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Henry Schein in a note issued to investors on Tuesday, March 17th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.20 per share for the quarter, down from their prior forecast of $1.22. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q3 2026 earnings at $1.43 EPS, Q4 2026 earnings at $1.44 EPS, FY2026 earnings at $5.26 EPS, Q1 2027 earnings at $1.28 EPS, Q2 2027 earnings at $1.38 EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at $1.62 EPS, FY2027 earnings at $5.76 EPS and FY2028 earnings at $6.28 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the prior year, the company posted $1.19 earnings per share. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Wells Fargo & Company raised their target price on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Robert W. Baird set a $100.00 price target on Henry Schein and gave the company an “outperform” rating in a research note on Monday, February 23rd. JPMorgan Chase & Co. boosted their price target on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Mizuho upped their price objective on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Henry Schein presently has an average rating of “Hold” and an average price target of $85.58.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $73.12 on Thursday. The company has a 50 day moving average of $77.96 and a 200-day moving average of $72.97. Henry Schein has a 1-year low of $60.56 and a 1-year high of $89.29. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. The company has a market cap of $8.39 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 2.22 and a beta of 0.88.

Insider Buying and Selling at Henry Schein

In related news, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director directly owned 15,420 shares in the company, valued at $1,217,563.20. This trade represents a 15.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Philip A. Laskawy sold 2,844 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the sale, the director directly owned 21,961 shares in the company, valued at $1,764,785.96. The trade was a 11.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 104,556 shares of company stock worth $8,476,351 in the last 90 days. Corporate insiders own 1.08% of the company’s stock.

Institutional Trading of Henry Schein

Institutional investors have recently modified their holdings of the business. AQR Capital Management LLC grew its position in shares of Henry Schein by 47.3% in the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after buying an additional 9,756 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Henry Schein by 1.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Henry Schein during the first quarter worth about $676,000. Allworth Financial LP lifted its stake in shares of Henry Schein by 39.2% in the second quarter. Allworth Financial LP now owns 1,640 shares of the company’s stock worth $120,000 after acquiring an additional 462 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Henry Schein by 4.7% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 29,853 shares of the company’s stock valued at $2,181,000 after acquiring an additional 1,340 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein News Summary

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks raised full-year and multi-year expectations — FY2026 EPS was nudged up to $5.26 (from $5.23), FY2027 to $5.76 (from $5.68) and Zacks published an FY2028 estimate of $6.28, suggesting stronger medium-term earnings power. MarketBeat HSIC
• Positive Sentiment: Zacks upgraded several quarterly estimates (examples: Q3 2026 to $1.43, Q4 2026 to $1.44, Q3 2027 to $1.49 and Q4 2027 to $1.62), which supports the raised full-year views and points to improving margins or revenue trajectory in later quarters. MarketBeat HSIC
• Neutral Sentiment: Positive analyst write-up from Zacks highlights Henry Schein as a “strong growth stock” based on style scores — useful context for investor sentiment but not a primary driver of near-term moves. Here’s Why Henry Schein (HSIC) is a Strong Growth Stock
• Positive Sentiment: Reputational boost: Henry Schein was named one of Ethisphere’s 2026 World’s Most Ethical Companies for the 15th consecutive year — a quality signal that can support investor confidence over time. Ethisphere Names Henry Schein as One of the 2026 World’s Most Ethical Companies
• Negative Sentiment: Near-term cuts to quarterly estimates: Zacks trimmed Q1 2026 to $1.20 (from $1.22) and lowered Q1 2027 and Q2 2027 forecasts (Q1 2027 to $1.28 from $1.35; Q2 2027 to $1.38 from $1.47). These nearer-term downgrades likely pressured the stock despite the longer-term upgrades. MarketBeat HSIC

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.